BNIP3 and pancreatic ductal adenocarcinoma: Moreover, scientific evidence has confirmed a close association between BNIP3 silencing and chemoresistance acquisition to 5-FU [10,17] and oxaliplatin [16] in colorectal cancer, and to gemcitabine and 5-FU in pancreatic ductal adenocarcinoma [14].